| ［1］ |
Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer[J]. Lancet, 2021, 397(10272): 428-444.
|
| ［2］ |
Ilyas SI, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111.
|
| ［3］ |
Islami F, Miller KD, Siegel RL, et al. Disparities in liver cancer occurrence in the United States by race/ethnicity and state[J]. CA Cancer J Clin, 2017, 67(4): 273-289.
|
| ［4］ |
Shin DW, Moon SH, Kim JH. Diagnosis of cholangiocarcinoma[J]. Diagnostics (Basel), 2023, 13(2): 233.
|
| ［5］ |
Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6): 1215-1229.
|
| ［6］ |
Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota?[J]. Nat Rev Microbiol, 2009, 7(12): 887-894.
|
| ［7］ |
Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project[J]. Nature, 2007, 449(7164): 804-810.
|
| ［8］ |
Thiennimitr P, Yasom S, Tunapong W, et al. Lactobacillus paracasei HII01, xylooligosaccharides, and synbiotics reduce gut disturbance in obese rats[J]. Nutrition, 2018, 54: 40-47.
|
| ［9］ |
Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21[J]. Gastroenterology, 2017, 152(4): 851-866, e24.
|
| ［10］ |
Park W, Lee SK, Gwack J, et al. Dysbiosis of bile microbiota in cholangiocarcinoma patients: A comparison with benign biliary diseases[J]. Int J Mol Sci, 2025, 26(4): 1577.
|
| ［11］ |
Miyabe K, Chandrasekhara V, Wongjarupong N, et al. Potential role of inflammation-promoting biliary microbiome in primary sclerosing cholangitis and cholangiocarcinoma[J]. Cancers (Basel), 2022, 14(9): 2120.
|
| ［12］ |
Di Ciaula A, Baj J, Garruti G, et al. Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk[J]. J Clin Med, 2020, 9(8): 2648.
|
| ［13］ |
Binda C, Gibiino G, Coluccio C, et al. Biliary diseases from the microbiome perspective: how microorganisms could change the approach to benign and malignant diseases[J]. Microorganisms, 2022, 10(2): 312.
|
| ［14］ |
Yong X, Tang B, Li BS, et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways[J]. Cell Commun Signal, 2015, 13: 30.
|
| ［15］ |
Jans M, Kolata M, Blancke G, et al. Colibactin-driven colon cancer requires adhesin-mediated epithelial binding[J]. Nature, 2024, 635(8038): 472-480.
|
| ［16］ |
Donald K, Finlay BB. Early-life interactions between the microbiota and immune system: impact on immune system development and atopic disease[J]. Nat Rev Immunol, 2023, 23(11): 735-748.
|
| ［17］ |
Zhou CB, Zhou YL, Fang JY. Gut microbiota in cancer immune response and immunotherapy[J]. Trends Cancer, 2021, 7(7): 647-660.
|
| ［18］ |
Chochi K, Ichikura T, Kinoshita M, et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells[J]. Clin Cancer Res, 2008, 14(10): 2909-2917.
|
| ［19］ |
Zhang Q, Ma C, Duan Y, et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma[J]. Cancer Discov, 2021, 11(5): 1248-1267.
|
| ［20］ |
Nie Q, Luo X, Wang K, et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway[J]. Cell, 2024, 187(11): 2717-2734, e33.
|
| ［21］ |
桑慧, 李文洁, 周颖, 等. 胆汁酸、肠道微生物与胆管癌发生和发展关系的研究进展[J]. 中华肝脏病杂志, 2021, 29(5): 493-496.
|
| ［22］ |
Yang R, Qian L. Research on gut microbiota-derived secondary bile acids in cancer progression[J]. Integr Cancer Ther, 2022, 21: 15347354221114100.
|
| ［23］ |
Larabi AB, Masson H, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function[J]. Gut Microbes, 2023, 15(1): 2172671.
|
| ［24］ |
Zhang L, Chen C, Chai D, et al. Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma[J]. Front Microbiol, 2022, 13: 1090392.
|
| ［25］ |
Jia X, Lu S, Zeng Z, et al. Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 71(3): 893-906.
|
| ［26］ |
Zhang T, Zhang S, Jin C, et al. A predictive model based on the gut microbiota improves the diagnostic effect in patients with cholangiocarcinoma[J]. Front Cell Infect Microbiol, 2021, 11: 751795.
|
| ［27］ |
Deng T, Li J, He B, et al. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer[J]. Hepatol Int, 2022, 16(1): 99-111.
|
| ［28］ |
Lederer AK, Rasel H, Kohnert E, et al. Gut microbiota in diagnosis, therapy and prognosis of cholangiocarcinoma and gallbladder carcinoma-a scoping review[J]. Microorganisms, 2023, 11(9): 2363.
|
| ［29］ |
Saab M, Mestivier D, Sohrabi M, et al. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma[J]. PLoS One, 2021, 16(3): e0247798.
|
| ［30］ |
Ye F, Shen H, Li Z, et al. Influence of the biliary system on biliary bacteria revealed by bacterial communities of the human biliary and upper digestive tracts[J]. PLoS One, 2016, 11(3): e0150519.
|
| ［31］ |
Li Z, Chu J, Su F, et al. Characteristics of bile microbiota in cholelithiasis, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and pancreatic cancer[J]. Am J Transl Res, 2022, 14(5): 2962-2971.
|
| ［32］ |
Shah A, Macdonald GA, Morrison M, et al. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: A conceptional framework[J]. Am J Gastroenterol, 2020, 115(6): 814-822.
|
| ［33］ |
Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer[J]. Nat Rev Microbiol, 2014, 12(10): 661-672.
|
| ［34］ |
Chai X, Wang J, Li H, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma[J]. Gut Microbes, 2023, 15(1): 2156255.
|
| ［35］ |
Liu S, Moon CD, Zheng N, et al. Opportunities and challenges of using metagenomic data to bring uncultured microbes into cultivation[J]. Microbiome, 2022, 10(1): 76.
|
| ［36］ |
Chng KR, Chan SH, Ng A, et al. Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in opisthorchis viverrini associated cholangiocarcinoma[J]. EBioMedicine, 2016, 8: 195-202.
|
| ［37］ |
Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer[J]. Science, 2021, 371(6536): eabc4552.
|
| ［38］ |
Capuozzo M, Santorsola M, Landi L, et al. Evolution of treatment in advanced cholangiocarcinoma: old and new towards precision oncology[J]. Int J Mol Sci, 2022, 23(23): 15124.
|
| ［39］ |
中国人民解放军三〇二医院. 肠道微生物作为胆管细胞癌诊断标志物的用途: 中国, CN202010915799.1[P]. 2021–02–05.
|
| ［40］ |
温州医科大学附属第一医院. 基于肠道微生物的胆管癌非侵入性标志物筛选、分析方法及应用: 中国, CN202011341383.8[P]. 2022–02–15.
|
| ［41］ |
Lee H, Lee HK, Min SK, et al. 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer[J]. World J Surg Oncol, 2020, 18(1): 19.
|
| ［42］ |
Qin H, Yuan B, Huang W, et al. Utilizing gut microbiota to improve hepatobiliary tumor treatments: recent advances[J]. Front Oncol, 2022, 12: 924696.
|
| ［43］ |
杜春明, 王春波, 郭云昌, 等. 益生菌与益生元对人体肠道正常菌群的调节作用[J]. 中国食品卫生杂志, 2005, 17(5): 440-441.
|
| ［44］ |
Amiri Khosroshahi R, Zeraattalab-Motlagh S, Sarsangi P, et al. Effect of probiotic supplementation on chemotherapy-and radiotherapy-related diarrhoea in patients with cancer: An umbrella review of systematic reviews and meta-analyses[J]. Br J Nutr, 2023, 130(10): 1754-1765.
|
| ［45］ |
Blake SJ, Wolf Y, Boursi B, et al. Role of the microbiota in response to and recovery from cancer therapy[J]. Nat Rev Immunol, 2024, 24(5): 308-325.
|
| ［46］ |
Agnes A, Puccioni C, D’Ugo D, et al. The gut microbiota and colorectal surgery outcomes: facts or hype? A narrative review[J]. BMC Surg, 2021, 21(1): 83.
|
| ［47］ |
Shogan BD, Chen J, Duchalais E, et al. Alterations of the rectal microbiome are associated with the development of postoperative ileus in patients undergoing colorectal surgery[J]. J Gastrointest Surg, 2020, 24(7): 1663-1672.
|
| ［48］ |
Yu J, Zhu P, Shi L, et al. Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma[J]. Cell Host Microbe, 2024, 32(1): 131-144, e6.
|
| ［49］ |
Re OL, López-López V, Balaguer-Román A, et al. New challenges in cholangiocarcinoma candidates for elective surgery: harnessing the microbiome dysbiosis[J]. Langenbecks Arch Surg, 2023, 408(1): 134.
|
| ［50］ |
Li Z, Zhang Y, Hong W, et al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma via STING signaling[J]. Gut Microbes, 2022, 14(1): 2119055.
|
| ［51］ |
Chen J, Levy A, Tian AL, et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients[J]. Cancer Cell, 2025, 43(3): 361-379,e10.
|
| ［52］ |
Silveira M, Bilodeau S, Greten TF, et al. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis[J]. Trends Cancer, 2022, 8(7): 583-597.
|
| ［53］ |
He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity[J]. Cell Metab, 2021, 33(5): 988-1000, e7.
|
| ［54］ |
Mao J, Wang D, Long J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9(12): e003334.
|
| ［55］ |
Di Carlo P, Serra N, D’Arpa F, et al. The microbiota of the bilio-pancreatic system: A cohort, STROBE-compliant study[J]. Infect Drug Resist, 2019, 12: 1513-1527.
|
| ［56］ |
Ye C, Zhang B, Lin Y, et al. Characteristics of gut microbiota and metabolites in extrahepatic cholangiocarcinoma and their prognostic value for resectable lesions[J]. Front Cell Infect Microbiol, 2025, 15: 1523863.
|
| ［57］ |
孙诚谊, 华豪. 微生物群对胰腺癌免疫治疗影响的研究现状[J/OL]. 中华普通外科学文献（电子版）, 2022, 16(6): 397-401.
|
| ［58］ |
Wheatley RC, Kilgour E, Jacobs T, et al. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy[J]. Br J Cancer, 2022, 126(5): 693-705.
|
| ［59］ |
Antushevich H. Fecal microbiota transplantation in disease therapy[J]. Clin Chim Acta, 2020, 503: 90-98.
|